CENTER FOR DRUG EVALUATION AND RESEARCH

ADVISORY COMMITTEE: PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE

DATE OF MEETING: 05/08/97

CENTER FOR DRUG EVALUATION AND RESEARCH

ADVISORY COMMITTEE: PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE

DATE OF MEETING: 05/08/97

SUMMARY MINUTES

Food and Drug Administration
Center for Drug Evaluation and Research

SUMMARY MINUTES OF THE PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE MEETING (46th)

May 8, 1997

Holiday Inn, Bethesda, MD

Members Present
Anti-Infective Drugs

Sid Gilman, M.D., Chair
Patricia Coyle, M.D.
Chris Gennings, Ph.D.
Ellyn Phillips, M.S.
Justin Zivin, M.D., Ph.D.
Harold Adams, M.D.
David Drachman, M.D.
Claudia Kawas, M.D.
Zaven Khachaturian, Ph.D.

FDA Participants
John Feeney, M.D.
David Hoberman, Ph.D.
Russell Katz, M.D.
Paul Leber, M.D.
Robert Temple, M.D.

Executive Secretary
Ermona McGoodwin

These summary minutes for the May 8, 1997, meeting of the Peripheral and Central Nervous System Drugs Advisory Committee were approved on 1-15-98.

I certify that I attended the May 8, 1997 meeting and that these minutes accurately reflect what transpired.

Ermona B. McGoodwin
Executive Secretary

Sid Gilman
Sid Gilman, M.D.
Chairperson

THURSDAY, MAY 8, 1997
Holiday Inn, Bethesda, MD

OPEN SESSION

The Peripheral and Central Nervous System Drugs Advisory Committee met in open session Thursday, May 8, 1997. Approximately 400 persons attended the meeting. As background material, the participants received the FDA Overview, the Medical Officer's review, Draft Guidance: "Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products," and a summary briefing document provided by the sponsor. **Dr. Sid Gilman,** Chair of the Committee, opened the meeting at 8:31 a.m. The **Conflict of Interest Statement** noted that full waivers were granted to Dr. Gilman, Dr. Zivin, and Ms. Phillips.

AGENDA

ISSUE: **NDA 20-654 Myotrophin® (mecasermin [recombinant DNA origin] Injection, Chephalon-Chiron Partners) for treatment of amyotrophic lateral sclerosis (ALS).**

FDA INTRODUCTION

Dr. Leber, Director, Division of Neuropharmacological Drug Products, provided an overview of FDA regulatory requirements for drug approval and outlined the charge to the Committee in evaluating the results of the data from the clinical trials for Myotrophin®.

SPONSOR PRESENTATIONS

Drs. Graney, Scharschmidt, Braekman, Vaught, and Miller, (Cephalon-Chiron Partners) discussed the clinical trials for Myotrophin Injection (rhIGF-1) a recombinant DNA-derived human insulin-like growth factor-I, also known as recombinant mecasermin. In animal studies (mice and rats) the drug has been shown to promote axonal regeneration and neuromuscular function. Based on this information, the Sponsor conducted 2 placebo-controlled human trials (1 domestic and 1 foreign) in ALS patients. Efficacy measures were the Appel ALS rating scale (physician assessment) and the Sickness Impact Profile (SIP) (patient-based health-related quality of life assessment). At 9 months the North American Study 1200 (266 patients) showed a statistically significant between group difference (p value 0.01) for the 0.1 mg/kg/day dose, but did not show a statistically significant between group difference for the 0.05 mg/kg/day dose.

QUESTION 2:

If not, do the findings of any single adequate and well controlled clinical investigation lend support to a conclusion that Myotrophin® is an effective treatment for ALS?

VOTE: YES = 9 (Unanimous)

QUESTION 3:

If so, can the Committee, on the strength of the evidence provided in this single study and taking into account the failure of the only other completed adequate and well controlled clinical investigation to confirm its findings, conclude that there is substantial evidence that Myotrophin® is effective in the treatment of ALS?

VOTE: NO = 6, Yes = 3 (3 members thought approval could be based on the North American study in view of the uniformly fatal and dreadful nature of the disease).

The meeting was adjourned at 6:42 p.m.